IRVINE, CA, and HERSTAL, BELGIUM – July 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced the appointment of Michael Holder to its Board of Directors as the Chair of the Audit Committee. Mr. Holder will take the seat of Regine Slagmulder, whose term completed in May. Mr. Holder is a highly accomplished executive with over 30 years of diverse experience, including nine board, four CEO, and five CFO roles across publi ...

MDxHealth (MDXH) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Company Participants John Fraunces - DirectorMichael McGarrity - CEO & Executive DirectorRon Kalfus - Chief Financial OfficerNelson Cox - Equity Research Associate Conference Call Participants Andrew Brackmann - Research Analyst - HealthcareMark Massaro - MD & Senior Equity Research AnalystDaniel Brennan - Senior Equity Research Analyst - Managing DirectorJason Bednar - Senior Research AnalystThomas Vranken - Associate Director, Equity Research ...

MDxHealth (MDXH) Q1 2025 Earnings Call May 14, 2025 04:30 PM ET Speaker0 note this event is being recorded. I would now like to turn the conference over to mister John Fernandez with LifeSci Advisors. Please go ahead. Speaker1 Good afternoon, and thank you for joining us for the MDX Health first quarter twenty twenty five earnings conference call. Joining me on today's call are Michael McGarity, Chief Executive Officer and Ron Kalpas, Chief Financial Officer. Before we begin, I would like to remind everyone ...

Year-over-year Q1 revenues increase by 22% to $24.3 million71% year-over-year improvement in adjusted EBITDA in first quarterConference call with Q&A today at 4:30 PM ET / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – May 14, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the first quarter ended March 31, 2025. Michael K. McGarrity, CEO of mdxhealth, commented: “mdxhealth delivered a strong ...

Exhibit 99.1 1. Report of the board of directors This report of the board of directors has been prepared in accordance with the Articles 3:5, 3:6, §1 and 3:32, §1 of the Belgian Companies and Associations Code of 23 March 2019 (as amended) (the "Belgian Companies and Associations Code" or "BCAC") and relates to the position of MDxHealth SA, a company domiciled and incorporated in Belgium (the "Company", and together with its subsidiaries, "MDxHealth"), and the Company's statutory and consolidated annual acc ...

Company to Host Conference Call with Live Q&A, May 14, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – April 30, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the first quarter ended March 31, 2025, after market close on Wednesday, May 14, 2025. Title:Mdxhealth Presents First Quarter 2025 Financial Results andCorporate Update Conference Call and WebcastSpeakers:Michael K. McGarrity, Chief Executive ...

MDxHealth SA (NASDAQ:MDXH) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants John Fraunces - LifeSci Advisors, IR Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Andrew Brackmann - William Blair Thomas Vranken - KBC Securities Jason Bednar - Piper Sandler Vidyun Bais - BTIG Dan Brennan - TD Cowen Operator Good day. And welcome to the MDxHealth Fourth Quarter and Full Year 2024 Earnings ...

Exhibit 99.1 Mdxhealth Announces Fourth Quarter and Full-Year 2024 Financial Results Fourth quarter revenue growth of 28% to $24.7 million 2024 revenue growth of 28% to $90.0 million 68% improvement in adjusted EBITDA in fourth quarter Conference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, CA, and HERSTAL, BELGIUM – February 26, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today announced its financial results for the ...

Core Insights - MDxHealth reported a strong financial performance for Q4 2024, with revenue growth of 28% to $24.7 million and a full-year revenue increase of 28% to $90.0 million [1][9] - The company achieved a 68% improvement in adjusted EBITDA for Q4, indicating progress towards profitability [8][9] - CEO Michael K. McGarrity emphasized the company's commitment to sustainable growth and the strong demand for its precision diagnostics [3] Financial Performance - Q4 2024 revenue was $24.7 million, up from $19.4 million in Q4 2023, marking a 28% increase [5][6] - Full-year revenue reached $90.0 million, compared to $70.2 million in 2023, also a 28% increase [8][9] - Gross profit for Q4 increased by 22% to $15.5 million, with gross margins at 62.7%, down from 65.3% in the prior year [6][10] - Operating expenses rose 6% to $20.1 million in Q4, driven by R&D and other operational costs [7][11] - The net loss for Q4 decreased by 36% to $6.8 million, compared to $10.7 million in Q4 2023 [7][12] Adjusted EBITDA - Adjusted EBITDA for Q4 was ($1.4) million, reflecting a 68% improvement from ($4.4) million in the same period last year [8][9] - For the full year, adjusted EBITDA was ($14.7) million, a 24% improvement compared to ($19.4) million in 2023 [12][25] Market and Product Insights - Tissue-based tests accounted for 81% of Q4 2024 revenue, up from 76% in Q4 2023 [6][8] - The volume of tissue-based tests increased by 50% year-over-year, while liquid-based tests saw a 10% increase [9] Outlook - The company maintains its 2025 revenue guidance of $108-110 million and anticipates achieving adjusted EBITDA profitability in the first half of 2025 [14]

Group 1 - MDxHealth SA will release its financial results for Q4 and full year 2024 on February 26, 2025, after market close [1][2] - The conference call will be hosted by CEO Michael K. McGarrity and CFO Ron Kalfus at 4:30 PM ET / 22:30 CET [2] - Dial-in details for the conference call are provided for various countries including the United States, Belgium, the Netherlands, and the United Kingdom [2] Group 2 - MDxHealth is a leading precision diagnostics company specializing in actionable molecular information for personalized patient diagnosis and treatment [3] - The company's tests utilize proprietary genomic, epigenetic, and other molecular technologies to assist in the diagnosis and prognosis of urologic cancers and diseases [3] - MDxHealth has its U.S. headquarters in Irvine, California, and additional laboratory operations in Plano, Texas, with European headquarters in Herstal, Belgium [3]